News & Press Releases Swedish

Scandinavian ChemoTechs Animal Care-division får order från Australien och USA

Scandinavian ChemoTechs helägda dotterbolag Vetiqure AB har erhållit order på vetIQure-TSE system från sin distributör i Australien. Detta efter att en studie med vetIQure fått ett etikgodkännande. Samtidigt har Vetiqure skrivit utvärderingsavtal med två klinker i USA. Totala ordervärdet för de båda affärerna uppgår till minst 17 000 euro.

Read more

Scandinavian ChemoTech publicerar klinisk strategiuppdatering från Medical Director Dr Suhail Mufti

Scandinavian ChemoTech har publicerat en uppdaterad klinisk strategi från bolagets Medical Director Dr Suhail Mufti.

Read more

TSE-behandlingar vid Royal Veterinary College visar mycket lovande resultat

Scandinavian ChemoTechs helägda dotterbolag Vetiqure får mycket lovande uppdateringar från veterinärerna på Royal Veterinary College (RVC) som nu kommer att behandla fler patienter med ChemoTechs tumörspecifika elektroporationsteknik (TSE).

Read more

News & Press Releases English

Scandinavian ChemoTech's Animal Care division receives orders from Australia and the US

Scandinavian ChemoTech's wholly owned subsidiary Vetiqure AB has received an order for vetIQure-TSE system from its distributor in Australia. This after a study with vetIQure received ethics approval. Vetiqure has also signed evaluation agreements with two clinics in the US. The total order value for both deals amounts to at least 17,000 euros.

Read more

Scandinavian ChemoTech publishes clinical strategy update from Medical Director Dr. Suhail Mufti

Scandinavian ChemoTech has published an updated clinical strategy from the company´s Medical Director Dr. Suhail Mufti.

Read more

TSE treatments at the Royal Veterinary College shows very promising results

Scandinavian ChemoTech’s fully owned subsidiary Vetiqure receives very promising updates from the veterinarians at the Royal Veterinary College (RVC), who will now continue to treat more patients.

Read more

ChemoTech Videos

2023

Clinical strategy update from Medical Director Dr. Suhail Mufti

Redeye Fight Cancer Day 2023 - ChemoTech

2022

ChemoTech 2022 - Mohan Frick CEO summarises the year (Swedish)

ChemoTech Q2 2022 - Livestream Presentation (in Swedish)

SWECARE at EXPO 2020 DUBAI: "Closing Ceremony"

A conversation with Småbolagspodden

(Audio in Swedish)

I det senaste avsnittet av Småbolagspodden berättar Scandinavian ChemoTechs vd Mohan Frick om hur bolagets unika metod för cancerbehandling, via så kallad tumörspecifik elektroporation, ska hjälpa människor och djur världen över.

Lyssna på hela avsnittet här:
52. ChemoTech – Vill vara en kraft för skonsammare cancervård

2021

Presentation of Q3 - Analysera med oss November 2021 (Swedish)

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

Innovative TSE technology increases the local effect of chemotherapy (Swedish)

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish) 8 January 2021

Videos from 2020

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in electroporation forms the starting point for the company’s existing product and R&D projects: The IQwave™ specially designed for our TSE™ – Tumour Specific Electroporation technology which treats a range of various tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.